[1] Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843.
[2] Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736–88. https://doi.org/10.1016/S0140-6736(18)32203-7.
[3] Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care 2018;41:963–70. https://doi.org/10.2337/dc17-1962.
[4] Powers AC, Niswender KD, Rickels MR. Diabetes mellitus: management and therapies. In: Jameson Jl, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 20th ed., New York, USA: McGraw-Hill Education; 2018, p. 2859.
[5] Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:10. https://doi.org/10.2337/dc06-9912.
[6] Schwartz SL, Wu JF, Berner B. Metformin extended release for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2006;7:803–9. https://doi.org/10.1517/14656566.7.6.803.
[7] Fujita Y, Inagaki N. Metformin: new preparations and nonglycemic benefits. Curr Diab Rep 2017;17:5. https://doi.org/10.1007/s11892-017-0829-8.
[8] Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–701. https://doi.org/10.2337/dci18-0033.
[9] Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med 2011;123:15–23. https://doi.org/10.3810/pgm.2011.01.2241.
[10] Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 2017;19:473–81. https://doi.org/10.1111/dom.12854.
[11] Schwartz SL, Gordi T, Hou E, Cramer M, Heritier M, Cowles VE. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. Expert Opin Drug Metab Toxicol 2008;4:1235–43. https://doi.org/10.1517/17425255.4.9.1235.
[12] Chacra AR. Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy. Am J Ther 2014;21:198–210. https://doi.org/10.1097/MJT.0b013e318235f1bb.
[13] Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.
[14] Ma J, Liu W, Hunter A, Zhang W. Performing meta-analysis with incomplete statistical information in clinical trials. BMC Med Res Methodol 2008;8:56. https://doi.org/10.1186/1471-2288-8-56.
[15] Metformin SR tablet (DuLeNing) and glucophage in patients with type 2 diabetes (CQM-2016). ClinicalTrialsGov 2019. https://clinicaltrials.gov/ct2/show/NCT03039075.
[16] Derosa G, D’Angelo A, Romano D, Maffioli P. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Design Dev Ther 2017;11:1481–8. https://doi.org/10.2147/DDDT.S131670.
[17] Kim J-D, Park C-Y, Cha B-Y, Ahn KJ, Kim IJ, Park KS, et al. Comparison of adherence to glimepiride/metformin sustained release once-daily versus glimepiride/metformin immediate release BID fixed-combination therapy using the medication event monitoring system in patients with type 2 diabetes. Clin Ther 2018;40:752–61. https://doi.org/10.1016/j.clinthera.2018.04.002.
[18] Schwartz S, Fonseca V, Berner B, Cramer M, Chiang Y-K, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29:759–64. https://doi.org/10.2337/diacare.29.04.06.dc05-1967.
[19] Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003;25:515–29. https://doi.org/10.1016/S0149-2918(03)80093-0.
[20] Hwang Y-C, Kang M, Ahn CW, Park JS, Baik SH, Chung DJ, et al. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. Int J Clin Pract 2013;67:236–43. https://doi.org/10.1111/ijcp.12071.
[21] Ghorpade V, Hiray R, Daswani B, Ghongane B. Comparison of conventional and sustained-release formulation of metformin in type 2 diabetics. Int J Basic Clin Pharmacol 2016;5:274–80. https://doi.org/10.18203/2319-2003.ijbcp20160654.
[22] Hsieh C-H, He C-T, Lee C-H, Wu L-Y, Hung Y-J. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism 2007;56:1087–92. https://doi.org/10.1016/j.metabol.2007.03.018.
[23] Aggarwal N, Singla A, Mathieu C, Montanya E, Pfeiffer AFH, Johnsson E, et al. Metformin extended-release versus immediate-release: an international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. Diabetes Obes Metab 2018;20:463–7. https://doi.org/10.1111/dom.13104.
[24] Gao H, Xiao W, Wang C, Zhang J, Yang Y, Yang J, et al. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study: Effects of metformin XR in patients with type 2 diabetes. Int J Clin Pract 2008;62:695–700. https://doi.org/10.1111/j.1742-1241.2008.01733.x.
[25] Ji L, Liu J, Yang J, Li Y, Liang L, Zhu D, et al. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial. Diabetes Obes Metab 2018;20:1006–13. https://doi.org/10.1111/dom.13190.
[26] Hameed M, Khan K, Salman S, Mehmood N. Dose comparison and side effect profile of metformin extended release versus metformin immediate release. J Ayub Med Coll Abbottabad 2017;29:225–9.
[27] Sterne JAC, Egger M, Moher D. Addressing reporting biases. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, England, UK: John Wiley & Sons Ltd.; 2008, p. 310–4.
[28] Little RR, Rohlfing CL. The long and winding road to optimal HbA1c measurement. Clin Chim Acta 2013;418:63–71. https://doi.org/10.1016/j.cca.2012.12.026.
[29] Svensson E, Baggesen LM, Johnsen SP, Pedersen L, Nørrelund H, Buhl ES, et al. Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: population-based cohort study of 24,752 metformin initiators. Diabetes Care 2017;40:800–7. https://doi.org/10.2337/dc16-2271.
[30] März W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A, et al. HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol 2017;106:663–75. https://doi.org/10.1007/s00392-017-1106-1.
[31] Thomas D, Radji S, Benedetti A. Systematic review of methods for individual patient data meta-analysis with binary outcomes. BMC Med Res Methodol 2014;14:79. https://doi.org/10.1186/1471-2288-14-79.